No prospective studies have evaluated the effects of correction of iron deficiency anemia on insulin resistance in non-diabetic premenopausal women. We investigated this relationship in 54 non-diabetic premenopausal women with iron deficiency anemia. SUBJECTS AND METHODS: All patients were treated with oral iron preparations. Insulin resistance was calcu--lated with the Homeostasis Model Assessment formula. All patients were dichotomized by the median for age and BMI to assess how the relationship between iron deficiency anemia and insulin resistance was affected by age and BMI. RESULTS: Although the fasting glucose levels did not change meaningfully, statistically significant decreases were found in fasting insulin levels following anemia treatment both in the younger age (<40 years) (P=0.040) women and in the low BMI (<27 kg/m 2 ) (P=0.022) subgroups but not in the older age (≥40 years) and the high BMI (≥27 kg/m 2 ) subgroups. Post-treatment fasting insulin levels were positively correlated both with BMI (r=0.386, P=0.004) and post-treatment hemoglobin levels (r=0.285, P=0.036). Regression analysis revealed that the factors affecting post-treatment insulin levels were BMI (P=0.001) and post-treatment hemoglobin levels (P=0.030). CONCLUSION: Our results show that following the correction of iron deficiency anemia, insulin levels and HOMA scores decrease in younger and lean non-diabetic premenopausal women.
I
t is well known that complex interactions exist among insulin, insulin resistance, iron and anemia. A mutual relationship has been identified between insulin and iron metabolism. Insulin both stimulates the synthesis of ferritin and causes a rapid and marked stimulation of iron uptake of cells by redistributing transferin receptors from the intracellular compartment of the cell membrane to the cell surface. Regulation of iron uptake by insulin occurs in parallel with its effects on glucose transport. 2 On the other hand, insulin act t tion is also influenced by iron. Iron causes hyperinsut t linemia and insulin resistance by inhibition of insulin internalization and actions. 3 In fact, the initial and most common abnormality seen in conditions with iron overload is hepatic insulin resistance. 4 In previous animal studies, it has been shown that glucose turnover Age-and body mass index-dependent relationship between correction of iron deficiency anemia and insulin resistance in non-diabetic premenopausal women increases in iron deficiency, and this increase is primart t ily due to enhanced peripheral insulin responsiveness. 5t 8 Interestingly, there are some reports indicating that low iron status increases insulin sensitivity in lactotovo vegetarians. In addition, phlebotomy is followed by det t creases in serum glucose as well as by improvements in both betatcell secretion and peripheral insulin act t tion. 9, 10 Insulin plays an important role in regulation of erythropoiesis both with its ability to boost activity of the transcription factor, hypoxiatinducible factort1A (HIFt1A), and more directly as a growth factor influt t encing development of reticulocytes. 11 On the other hand, some recent reports suggest that rising hemoglot t bin/hematocrit (hemoglobin/hematocrit) levels are a component of insulin resistance syndrome, presumably due to the facilitative effect of insulin on erythropoietin synthesis. 12t14 Conversely, in patients with chronic renal failure, anemia has been suggested to be responsible for the insulin resistance commonly seen in these pat t tients.
15t18
Hyperinsulinemia and insulin resistance constitute a risk factor for atherosclerotic heart diseases. 19 It is commonly accepted that premenopausal women carry less risk for cardiovascular diseases essentially due to the protective effect of intrinsic estrogen hormone. 20 In premenopausal women, iron deficiency, which is usut t ally caused by menstrual loss, is a very common health problem. Some animal and human studies indicate that iron deficiency increases glucose tolerance and insulin sensitivity. In that case, low iron status in premenot t pausal women may exert an independent and additional protective role besides hormonal status for atherosclet t rotic heart diseases. To the best of our knowledge, there have not been any prospective studies reporting the eft t fects of correction of iron deficiency anemia on insut t lin resistance in nontdiabetic premenopausal women. In this prospective study, we investigated how insulin resistance is affected by correction of anemia and how this relationship might be affected by anthropological parameters such as age and BMI.
SUBJECTS AND METHODS
We recruited 54 anemic premenopausal women (ment t struating women of reproductive age) who had iron deficiency anemia due to menstrual loss (median age, 40 years; mean age, 36.28±10.64 years; range, 15 to 52 years) for this study. Serum ferritin values below the normal range and transferrin saturation below 15% were accepted as indicators of iron deficiency. Blood hemoglobin and hematocrit values below the normal range (≤12 g/dL and ≤35%, respectively) were accepted as indicators of anemia. All patients were treated with oral iron preparations (daily 225 mg ferroglycine sult t fate), and the median duration of treatment was three months. Patients were excluded from the study if they had family histories of diabetes mellitus, repeatedly had fasting venous serum glucose levels >110 mg/dL or were previously placed on iron replacement treatments. Previous medications other than iron preparations that had already being used by the patients were continued. Informed consent was obtained from each subject aft t ter approval of the experimental protocol by the local human ethics committee. For each patient included in this study, hemoglobin, hematocrit, serum iron, transt t ferrin saturation and serum ferritin were measured in 12thour fasting blood both prior to the onset of iron replacement and 15 days after stopping iron treatt t ment due to improvement of anemia. Both prettreatt t ment and postttreatment insulin and glucose levels were measured in three different venous serum samples taken within intervals of 5 minutes after 12 hours of fasting. Table 2 . Pre-and post-treatment laboratory parameters of low and high BMi subgroups. In all patients, we searched for the existence of a post t sible relationship between iron deficiency anemia and insulin resistance. All patients as a whole group were dichotomized by the median for age (<40 years, n=25 and ≥40 years, n=29) and BMI (<27 kg/m 2 , n=26 and ≥27 kg/m 2 , n=28) to assess how this relationship, if it existed, was affected by age and BMI.
Lean BMI High BMI P

Pretreatment
Statistical analysis was conducted using the Statistical Package for Social Sciences (SPSS, Inc, Chicago, IL, USA) for Windows 10.0 programs. Results were ext t pressed as means±standard deviation. Comparisons between pret and postttreatment levels were made by the paired T test. Simple (Pearson) correlation coeffit t cients between HOMAtIR and measures of variables were calculated, and a multiple linear regression analysis was performed, considering HOMAtIR as a dependent variable and all others as explanatory variables. Since the levels of HOMAtIR strictly depended on fasting insut t lin and glucose concentration, we did not consider these parameters in the multiple regression analysis. Results Table 3 . Pre-and post-treatment laboratory parameters of younger and older age subgroups.
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Older age P were analyzed with 95% confidence intervals and probt t ability levels less than 0.05 were considered significant.
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RESULTS
The patients included in this study had a mean BMI of 26.84±5.95 kg/m 2 , a mean waist/hip ratio of 0.82±0.10 and mean age of 36.28±10.64 years. When all 54 patients were assessed as a whole, statistically significant decreases were found in fasting insulin levt t els and HOMA scores following the correction of iron deficiency anemia while pretand postttreatment fasting glucose levels did not change meaningfully (Table 1 ). In the presence of anemia, neither fasting insulin levels nor HOMA scores were found to be significantly correlated with either hematological or iron parameters. After cort t rection of the anemia, both fasting insulin levels and HOMA scores were found to be positively correlated with both BMI and postttreatment hemoglobin levels, with statistical significance. In the regression analysis, the factors affecting postttreatment insulin levels were found to be BMI (P=0.001) and postttreatment hemot t globin levels (P=0.030).
When all the patients were dichotomized by the met t dian for BMI into two subgroups as low (mean BMI, 21.90±2.62; range, 17 to 26 kg/m 2 ) and high (mean BMI, 31.43±4,22; range, 27 to 44 kg/m 2 ) subgroups, the high BMI subgroup consisted of older patients than the low BMI subgroup (42.50±5.51 and 29.58±10.82 years, P<0.001, respectively). Neither prettreatment nor postttreatment levels of hemoglobin, hematocrit, serum iron, transferrin saturation, serum ferritin and fasting glucose differed significantly between the high and the low BMI subgorups. Also, prettreatment fasting insut t lin levels and HOMA scores in the high and low BMI subgroups did not differ significantly from each other, but the mean postttreatment fasting insulin levels and HOMA scores were found to be significantly lower in the low BMI subgroup than in the high BMI subgroup ( Table 2 ). The fasting glucose levels of the low and high BMI subgroups did not change meaningfully following iron treatment. After correction of the anemia, both int t sulin levels (from 9.18±7. 35 
DiScUSSion
The most important result of this study is that the ret t lationship between iron deficiency anemia and insulin levels (and HOMA scores, which are accepted as indit t cators of insulin resistance) seen in nontdiabetic pret t menopausal women is multitfactorial. Our results show that some anthropological parameters such as age and BMI have an influence on the relationship between iron deficiency anemia and insulin levels.
When all 54 patients were assessed as a whole, the results of this study differed from the results of animal and similar, but not identical, human studies, which ret t ported that iron deficiency increases glucose tolerance and insulin sensitivity.
5t9 According to our results, in general, following treatment of iron deficiency anemia, insulin levels and HOMA scores in premenopausal women decreased, with statistical significance. Our results showed that the decreases in insulin levels and HOMA scores actually occurred in patients of younger age and lower BMI. However, these parameters also showed a tendency to decrease rather than to increase in patients of older age and high BMI.
To the best of our knowledge, there are no published human studies that assess the relationship between iron deficiency anemia and insulin resistance other than reports indicating that low iron status enhances insulin sensitivity in lactotovo vegetarians. 9 Previously reported human studies investigating the relationship between anemia and insulin resistance usually consistt t ed of patients with diagnoses of either thalassemia 21t24 or aplastic anemia, 25 and in general, subjects with these diagnoses are considered to have simultaneous iron overload. The relationship between iron overload and insulin resistance is well known. 26 Patients with thalt t assemia and aplastic anemia have only the anemia fact t tor as the common denominator with iron deficient patients, and therefore, it would be a mistake to cont t sider these patients anemic, but at the same time iron overloaded patients are in the same category with iron deficient patients when evaluating insulin resistance. Our results also differ from the results of animal ext t periments showing that iron deficiency increases glut t cose tolerance primarily due to an increase in peripht t eral insulin responsiveness.
5t8 Similar studies have also been done with chronic renal failure patients in whom insulin resistance is accompanied with many other fact t tors, 15, 17, 27 and anemia has been suggested as the causal factor for insulin resistance in these patients. Moreover, it has been reported that insulin resistance is reduced or improved in these patients due to either the direct effect of erythropoietin treatment or the indirect effect of anemia correction. 15, 16, 27 With respect to anemia, our results are similar to the results of the studies done with patients with chronic renal failure. However, our results indicate that neither low iron status itself nor the ret t sultant anemia of iron deficiency are the causes of the higher insulin levels and HOMA scores.
In this study, the results of the subgroup analysis for age and BMI suggest that the anthropological charact t teristics of a study population may affect the relationt t ship between iron deficiency anemia and insulin resist t tance, so the contrary results found in this study could be due to the different anthropological characteristics of the study population. The reason for the different responses in means of insulin resistance to iron treatt t ment exerted by the younger age/low BMI and the older age/high BMI subgroups is not clear given that subjects were of the same gender and had similar hormonal stat t tus. We speculate that patients of younger age and low BMI are more energetic and active following the treatt t ment of anemia compared to patients of older age and higher BMI, and the expenditure of more energy might be an additional factor contributing to the reduction of insulin resistance. Also, the therapy duration of three months is not long enough to see the changes in the levt t els of insulin and HOMA scores in patients with older age and high BMI who already have established insulin resistance when compared with patients of younger age and low BMI. The results of these subgroup analyses indicate both the necessity of taking the anthropologit t cal characteristics of the study population into account while assessing the relationship between iron deficiency and insulin resistance, and the need for further studies with different population groups.
On the other hand, there are some recent reports suggesting that the rising of hemoglobin/hematocrit values might be a component of the insulin resistance syndrome.
12t14 In this study, we also found that there were statistically significant positive correlations bet t tween postttreatment hemoglobin levels and insulin levt t els as well as between postttreatment hemoglobin levels and HOMA scores. Also, regression analysis revealed that the factors affecting postttreatment insulin levels were BMI and postttreatment hemoglobin levels. These results of regression and correlation analyses provide support for the existence of a relationship between insut t lin resistance and hematological parameters. Therefore, when considering the treatment of iron deficiency anet t mia, targeting lower hemoglobin/hematocrit levels may be a suitable and a necessary action for patients of older age and higher BMI who already have established insut t lin resistance, and particularly for the patients in whom impaired glucose tolerance accompanies iron deficiency.
We do not know the exact underlying mechanism that explains the significant decrease in fasting insulin levels and HOMA scores after the treatment of iron deficiency anemia in premenopausal women. Also, we do not know whether the decrease in insulin levels and HOMA scores following iron therapy is due to iron ret t placement itself or correction of the resultant anemia. Although there are some reports showing that insulin promotes the synthesis of erythropoietin by boosting the activity of HIFt1A, which functions physiologit t cally as a detector of both hypoxia and irontdeficiency, 11 and induces the synthesis of glucose transporters as well as glycolytic enzymes, it is not known whether dit t minished activity of HIFt1A following iron therapy aft t fects the synthesis and secretion of insulin or not. Such a relationship, if it exists, could be responsible for the decrease in insulin levels and HOMA scores following iron replacement, so it is clear that this topic merits furt t ther investigation.
Due to the role of insulin resistance and irontdet t pendent oxidative stress in the onset and progression of atherosclerosis, the relationship between iron defit t ciency and insulin resistance has importance. Despite some contrary reports, 28, 29 it has been shown that there is a link between iron status and the pathogenesis of atherosclerosis.
30t35 Also, some evidence from previt t ously published data show that the progression of an atherosclerotic plaque can be decelerated by reducing body iron stores with phlebotomy. 31, 36 When the results of our study are assessed in this perspective, it can be concluded that iron deficiency has a reducing effect on insulin levels in patients of younger age and lower BMI in whom atherosclerosis and its complications are ext t pected to be less prevalent, whereas such an effect was not evident in patients of older age and higher BMI in whom atherosclerosis and its complications are expectt t ed to be more prevalent. This result is not compatible with the hypothesis that low iron status in premenot t pausal women may play an independent and additional protective role for atherosclerotic heart diseases.
In conclusion, our results show that an aget and BMItdependent relationship exists between iron defit t ciency anemia and insulin levels (and HOMA scores) in nontdiabetic premenopausal women. When cont t sidering the treatment of iron deficiency anemia, tart t geting lower hemoglobin/hematocrit levels may be an appropriate and a necessary action for the patients of older age and higher BMI, particularly for patients in whom impaired glucose tolerance accompanies iron det t ficiency.
